Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib plus Pimasertib in MAPK-Altered Solid Tumors
NCT07121829Phase 1Terminated
- Sponsor
- Day One Biopharmaceuticals
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tovorafenib in solid tumor, sponsored by Day One Biopharmaceuticals. Primary endpoints: Treatment emergent adverse events, Clinically significant changes in vital signs and 3 more. Started May 2022; status: terminated.
02
Drugs
tovorafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07121829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121829.